Acute aspirin plus cilostazol Dual Therapy for non-cardioembolic stroke patients within 48 h of symptom onset -a prospective, multicenter, randomized, an aspirin-controlled study-

Acute aspirin plus cilostazol Dual Therapy for non-cardioembolic stroke patients within 48 h of symptom onset -a prospective, multicenter, randomized, an aspirin-controlled study- - Acute aspirin plus cilostazol Dual Therapy for non-cardioembolis stroke

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004950

Enrollment

2000

Registered

2011-06-02

Start date

2011-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non cardioembolic stroke

Interventions

From May 2011 to April 2013 aspirin plus cilostazol group aspirin 81-200mg plus cilostazol 200mg From May 2011 to April 2013 aspirin group aspirin 81-200mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: non-cardioembolic stroke within 48 hours of onset NIHSS score on admission 20 points or over preadmission mRS score 0-2

Exclusion criteria

Exclusion criteria: cardioembolic stroke preadmission antithrombotic therapy (cilostazol, aspirin 200mg or over, clopidgrel, ticlopidine, anticoagulants) congestive heart failure pregnancy allergy

Design outcomes

Primary

Measure	Time frame
modified Rakin scale score at 3 months after stroke neurological worsening within 14 days of stroke onset TIA, stroke reccurence, intracerebral hemorrhage, subarachnoid hemorrhage within 14 days of stroke onset	—

Countries

Japan

Contacts

Public ContactTakeshi Inoue

Kawasaki Medical School Stroke Medicine

inouet@med.kawasaki-m.ac.jp086-462-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026